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Type 1 diabetes (T1D) is part of a group of disorders
termed “organ-specific autoimmune diseases”, involving
destructive inflammation focused on the insulin-produ-
cing beta cells in the islet of Langerhans. Patients (fre-
quently children) lose endogenous insulin production
and are required to inject insulin several times per day
for the remainder of their lives, and, after many years,
frequently develop severe life-threatening complications
affecting the kidneys, heart and eyes. Beta cell destruc-
tion is mediated by T lymphocytes. Our work has
focused on identification of the key epitopes of beta cell
autoantigens that T lymphocytes recognize during the
development of T1D. We have characterized autoreac-
tive CD4 T cells that produce the pro-inflammatory
cytokines IFN-gamma and IL-17 as well as others that
make IL-10; these have potent immune regulatory prop-
erties and are present in a subset of patients who have
delayed diabetes onset. More recently, we have extended
our analysis of the epitope repertoire in T1D to include
peptides presented by disease-associated MHC class I
molecules to CD8 T cells. We have identified novel epi-
topes in preproinsulin that are processed by an uncon-
ventional route and are targeted by cytotoxic T
lymphocytes (CTLs) in a high proportion of T1D
patients. Finally, we have used knowledge about epitopes
to explore the potential for antigen-specific immune
modulation in T1D, completingaf i r s t - i n - m a ns t u d yo f
proinsulin peptide immunotherapy in patients in order
to generate data on safety and biomarkers, and lay the
groundwork for future intervention studies designed to
examine efficacy.
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